 | Up a level |
Brooker, RC 
ORCID: 0000-0002-0668-6889, Hobkirk, A, Cashman, H, Sato, T, Broderick, D, Wong, H, Kyzas, P, Haridass, A, Sacco, JJ and Schache, AG ORCID: 0000-0001-9466-6038
(2021)
Adjuvant management of locally advanced oral squamous cell carcinoma – real world challenges and opportunities.
British Journal of Oral and Maxillofacial Surgery, 59 (8).
pp. 952-958.
Jama, N, Farquhar, N, Butt, Z ORCID: 0000-0002-8307-9812, Coupland, SE ORCID: 0000-0002-1464-2069, Sacco, JJ, Scase, T, Fielding, AB, Coulson, JM ORCID: 0000-0003-2191-2001, Kalirai, H ORCID: 0000-0002-4440-2576 and Killick, DR ORCID: 0000-0002-8787-7651
(2018)
Altered Nuclear Expression of the Deubiquitylase BAP1 Cannot be Used as a Prognostic Marker for Canine Melanoma.
Journal of Comparative Pathology, 162.
pp. 50-58.
Cheung, VTF, Gupta, T, Olsson-Brown, A, Subramanian, S ORCID: 0000-0002-6483-1730, Sasson, SC, Heseltine, J, Fryer, E, Collantes, E, Sacco, JJ, Pirmohamed, M ORCID: 0000-0002-7534-7266 et al (show 6 more authors)
(2020)
Immune checkpoint inhibitor-related colitis assessment and prognosis: can inflammatory bowel disease scoring point the way?
.
Brooker, RC ORCID: 0000-0002-0668-6889, Sacco, JJ and Schache, AG ORCID: 0000-0001-9466-6038
(2019)
Integration of Checkpoint Inhibitors into the Management of Locally Advanced Head and Neck Cancer - Future Perspectives.
Clinical Oncology, 31 (7).
pp. 424-431.
Cossar, LH, Schache, AG ORCID: 0000-0001-9466-6038, Risk, JM ORCID: 0000-0002-8770-7783, Sacco, JJ, Jones, NJ ORCID: 0000-0003-1801-1456 and Lord, R
(2017)
Modulating the DNA Damage Response to Improve Treatment Response in Cervical Cancer.
Clinical Oncology, 29 (9).
pp. 626-634.
Brooker, RC ORCID: 0000-0002-0668-6889, Schache, AG ORCID: 0000-0001-9466-6038 and Sacco, JJ
(2021)
NICO Phase II clinical trial - focus on an emerging immunotherapy strategy for the adjuvant treatment of locally-advanced oral cancers.
BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 59 (8).
pp. 959-962.